Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

Fig. 2

Co-exposure to panitumumab may enhance the efficacy of vemurafenib in some BRAFV600E CRC cells. a-f. Cell viability (a, c, e) and cell death (b, d, f) assessment in BRAFV600E mutant cells Colo205 and HT-29 and in SW-48 BRAFwt (EGFRmut) cell line, 48 h after the administration of 3 μM vemurafenib (VEM), or 8 μg/mL panitumumab (PAN) or the combination of the two (Vem + Pan). Histograms represent mean ± SD of three independent experiments *p < 0.05, **p < 0.01 vs CTRL; ° p < 0.05 vs VEM

Back to article page